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Abstract Children differ from adults in their response to
drugs. While this may be the result of changes in dose
exposure (pharmacokinetics [PK]) and/or exposure re-
sponse (pharmacodynamics [PD]) relationships, the magni-
tude of these changes may not be solely reflected by
differences in body weight. As a consequence, dosing
recommendations empirically derived from adults dosing
regimens using linear extrapolations based on body weight,
can result in therapeutic failure, occurrence of adverse
effect or even fatalities. In order to define rational, patient-
tailored dosing schemes, population PK–PD studies in
children are needed. For the analysis of the data, population
modelling using non-linear mixed effect modelling is the
preferred tool since this approach allows for the analysis of
sparse and unbalanced datasets. Additionally, it permits the
exploration of the influence of different covariates such as
body weight and age to explain the variability in drug
response. Finally, using this approach, these PK–PD studies
can be designed in the most efficient manner in order to
obtain the maximum information on the PK–PD parameters
with the highest precision. Once a population PK–PD
model is developed, internal and external validations should
be performed. If the model performs well in these
validation procedures, model simulations can be used to
define a dosing regimen, which in turn needs to be tested
and challenged in a prospective clinical trial. This method-
ology will improve the efficacy/safety balance of dosing
guidelines, which will be of benefit to the individual child.
Keywords Pharmacokinetics.Pharmacodynamics.
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Introduction
Children differ from adults in their response to drugs. These
differences may be caused by changes in the pharmacoki-
netics (PK) and/or pharmacodynamics (PD) between
children and adults and may also vary among children of
different ages. The PK of a drug includes the processes of
absorption, distribution, metabolism and elimination of a
drug, whereas the PD comprises the physiological and
biological response to the administered drug and therefore
may represent both efficacy and safety measures. While a
child grows, enzyme pathways (involved in the PK),
function and expression of receptors and proteins (involved
in the PD) mature, which can be referred to as “develop-
mental changes” in childhood. The maturation rates of these
developmental changes vary, however, between the path-
ways and receptors and often do not correlate solely with
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therefore how to obtain data in children that allow for the
study of these developmental changes, ultimately resulting
in evidence-based dosing regimens for drugs in children.
To date, only a small number of drugs used in children
are licensed for use in this specific group. Up to 70% of the
drugs in paediatric intensive care, and 90% of the drugs in
neonatal intensive care, are prescribed in an off-label or
unlicensed manner [1–4]. Paediatric dosing regimens are
usually empirically derived from adult regimens using
linear extrapolations based on body weight. Since these
developmental changes are non-linear dynamic processes,
this dosing paradigm may result in under- or over-dosing,
particularly in specific age groups. This may cause
therapeutic failure, occurrence of severe adverse effects or
even fatalities, such as fatalities occurring after long-term
sedation with high doses of propofol [5, 6] and occurrence
of the grey baby syndrome in neonates after treatment with
chloramphenicol [7, 8]. As a result, dose adjustments in the
younger age groups are often proposed. For vancomycin,
for example, lower doses are administered in neonates
younger than 1 week (20 mg/kg/day) compared with 1- to
4-week-old neonates (30 mg/kg/day) and children between
1 month and 18 years (40 mg/kg/day) [9].
Instead of the a priori use of body weight for dosing
guidelines in children, detailed information on PK and
potentially also the PD needs to be considered in order to
define effective and safe dosing regimens throughout the
paediatric age range. The lack of PK and PD information
on drugs in children has led to the European Regulation,
which came into force in 2007. This law imposes on
pharmaceutical companies to perform research over the
whole paediatric age range for all drugs that are developed
for the European market, by requiring the submission of a
paediatric investigational plan (PIP) in the early stages of
the development of a new drug. In this PIP, a full
description has to be given of the studies and of drug
formulation in the paediatric population. If little informa-
tion is available about the efficacy and safety of a drug,
studies in children are only performed after more informa-
tion has been obtained in the adult population to increase
the safety of the paediatric study [10–12]. The main aims of
introducing the paediatric regulation were to facilitate
development and availability of medicines in children aged
between 0 and 17 years, to improve the availability of
information about medicines used in children, to ensure that
the medicines are of high quality, can be administered in a
safe and effective way and that paediatric studies are
performed in an ethically correct way [10]. The reward for
this effort is a 6-month supplementary production certificate
for the pharmaceutical company.
Bothfor industryandforacademicresearchers,performing
(PK–PD) studies in children in order to develop rational
dosing schemes is very challenging because of ethical and
practical issues. Unlike studies in healthy adults, research in
healthy children is considered to be unethical,so all paediatric
studies are performed in the vulnerable group of children
sufferingfromadisease.Inallclinicaltrials,informedconsent
hastobesignedbythepatientbeforeheorshecanbeenrolled
into a trial. In paediatric trials, this informed consent cannot
be obtained by the patient that participates in the trial, and
is therefore replaced by the consent of the parents or
guardians. In older age groups, in addition to this consent,
an assent is used in which the aim of the study is explained
in age-appropriate language so that children can understand.
[1, 4, 13].
Apart from ethical issues, practical challenges also occur
when performing studies in children. There are limitations
to the number and volume of samples that can be obtained,
resulting in infrequent sampling possibilities and the need
for advanced drug assay techniques with improved sensi-
tivity. Another complicating factor is the limited available
number of subjects that suffer from the same disease.
Finally, pharmacodynamic endpoints that measure the
efficacy of the drug and that are validated for children
may be lacking. All these factors call for highly advanced
study designs and analysis techniques so that the burden for
each child can be kept to a minimum while still addressing
all the study objectives.
This article aims to inform clinical pharmacologists,
paediatricians and pharmacists about population PK–PD
modelling in paediatric drug research. Advanced statistical
tools are discussed that can be used to develop rational
dosing schemes based on the PK and PD of a drug in
children, despite practical and ethical restrictions. Using
these tools, covariates can be identified in order to define
appropriate doses and dosing intervals based on the
individual characteristics of each child with minimal burden
to each patient. The article also describes how to evaluate
the predictive performance of the models by different
validation methods including a prospective clinical trial.
Ultimately, the efforts result in an individualised dosing
regimen based on the PK–PD relation throughout the
paediatric age range.
PK–PD in children
Developmental changes in childhood can affect all PK
processes from absorption until elimination as well as the
pharmacodynamic effects. For example, in neonates intra-
gastric pH is elevated (>4), which may increase the
bioavailability of acid-labile compounds (penicillin G) and
decrease the bioavailability of weak acids (phenobarbital)
when given orally [14]. Additionally, gastric emptying in
neonates is delayed, which means that also the absorption
S6 Eur J Clin Pharmacol (2011) 67 (Suppl 1):S5–S16of drugs, e.g. paracetamol is slower in neonates [15, 16].
Other examples are changes in the metabolising enzyme
capacity in children. Although most uridine 5′-diphosphate
(UDP)-glucuronosyltransferases (UGTs) and P-450 cyto-
chromes (CYPs) are expressed during the first week of life,
the activity at birth in comparison with adults is often low,
e.g. UGT2B7 activity at birth is around 10% of the adult
level and different enzyme systems are known to mature at
different rates [14, 17–20].
In addition, renal function and liver flow are influenced
by physiological changes depending on age, e.g. the
glomerular filtration rate (GFR) in mL/min/70 kg in full-
term neonates is 35% of the adult value, while mL/min/
70 kg adult values are reached at approximately 1 year old
[21]). When using units of mL/min/70 kg, however, it
should be realised that actual values of GFR in children are
still very low compared with adult values because of the
correction for differences in total body weight between
adults and infants.
Furthermore, the body composition of children changes
continuously, resulting in an age-dependent proportion of
body water and fat, which influences the distribution of
drugs. For example, the total amount of body water (80–
90% of the body weight) is higher in neonates than in
adults (55–60%). Hydrophilic drugs like aminoglycosides
have a larger volume of distribution in neonates, which can
be explained by the larger amount of extra-cellular fluid
(45% of the body weight) compared with adults (20%)
[14, 22].
In order to characterise the specific influence of develop-
mental changes in childhood on the PK of a drug,
concentration–time profiles are necessary, which require
measurements of drug concentrations. For ethical reasons, in
paediatric studies, discomfort, like pain and anxiety associ-
ated with venipuncture, must be restricted and practical
issues limit the volume and amount of blood samples that
can be obtained. Therefore, sensitive analysis techniques
requiring only small blood samples should be used. While
HPLC methods have been reported to require only 50 μLo f
blood [23], more recently LC-MS methods can measure up
to ten different drugs in volumes as low as 50–100 μL[ 24].
Additionally, also alternative matrices such as saliva should
be explored as a non-invasive, more child-friendly alterna-
tive to measure a drug concentration. An example in this
respect is an LC-MS/MS method that was developed and
validated for the measurement of busulphan in saliva [24].
Also, the use of a dried blood spot method, e.g. for
tacrolimus, can facilitate the measurement of drugs in
children [25]. Another method is capillary electrophoresis,
which requires only a low sample volume for the
quantification of drugs in biological fluids [26].
Changesbetween children andadultsmayalso result from
differences in the pharmacodynamics of a drug in children,
e.g. by changes in the relative number and function of
receptors. These age-related PD differences are until present
rarely reported in the literature, but one of the few examples
istheincreasedsensitivitytod-tubocurarine,anantagonistof
nicotinic neuromuscular acetylcholine receptors, in neonates
and infants compared with children and adults [27]. Other
examples are the observed lower minimum alveolar
concentration (MAC) of isoflurane in pre-term neonates
compared with full-term neonates and older children [28,
29] and the different sensitivity to bronchodilators because
of the lack of smooth muscles in the airways in neonates
[30].
To study the PD of a drug in children, the use of a PD
endpoint that has been validated for use in children is a
prerequisite. An illustrative example is the measurement of
pain in young children. Since they are not able to report
their pain using a visual analogue scale, an observational
scale has been developed. This comfort behavioural
(COMFORT-B) scale was developed and validated for use
in children under the age of 3 years [31]. The scale assesses
six behavioural items: alertness, calmness, muscle tone,
body movement, facial tension and crying (non-ventilated
children) or respiratory response (ventilated children). All
items range from 1 (no distress) to 5 (severe distress),
resulting in a total score varying from 6 to 30. This
validated scale can then be used as a PD endpoint for the
development of PD models for pain and/or sedation in
children of different ages [32–34].
The influence of covariates such as the developmental
changes, disease status and genetics on the PK and PD of
drugs in children is depicted in Fig. 1.
When both the PK and PD of a drug in children are
characterised, the models developed can be used to derive
rational dosing regimens with predictable efficacy and
concentration profiles. An example of such a PK–PD
model with a derived dosing regimen is an article published
by Peeters et al. In this article both the PK and the PD were
characterised in children, the latter with the use of the
COMFORT-B scale as a pharmacodynamic endpoint [33].
Based on the model it was found that propofol clearance is
PK  Dose Concentration  Efficacy, Safety
Developmental changes, disease status and genetics
PD 
Fig. 1 Schematic representation of the relationship between dose and
concentration (pharmacokinetics, PK) and between concentration and
a pharmacological (side) effect (pharmacodynamics, PD). Important
covariates that may affect both the PK and/or PD are body weight,
age, disease status (e.g. critically ill versus healthy children) and
genetics
Eur J Clin Pharmacol (2011) 67 (Suppl 1):S5–S16 S7two times higher in non-ventilated children than in
ventilated children and adults. For the PD, a model was
derived in which an effect of propofol was characterised
within a naturally occurring sleep pattern of children in the
ICU. Both models (PK as well as PD) were used to
simulate concentrations as well as the effects that could be
expected using different dosing schemes (Fig. 2). As a
result, based on this PK–PD model, a propofol dose of
30 mg/h was recommended for a child of 10 kg, which will
result in adequate COMFORT-B scales in the night
following craniofacial surgery.
Methods of analysing data: standard two-stage
or population approach
When concentration–time and concentration–effect datasets
obtained in children are considered for analysis, two
different methods can be applied: the standard two-stage
approach and the population approach using non-linear
mixed effect models [35–38]. When using the standard
two-stage approach or classical approach, in a first step
parameters are estimated in each individual based on
individual concentration–time profiles (Fig. 3a). In a second
step, these parameters are summarised by calculating the
mean or median of the parameters and the variability
between subjects (SE or IQR). A major drawback of this
methodology is that it requires a relatively high number of
samples in each individual patient (Fig. 3a), while each
patient has to contribute roughly the same number of
samples. Moreover, it is very difficult to distinguish
between inter-individual (variability between subjects) and
intra-individual or residual variability (variability within
one subject, measurement error and model misspecifica-
tion) and as a result inter-individual variability is often
overestimated [39].
Since usually only a limited number of observations can
be obtained in paediatric subjects, the population approach
using non-linear mixed effect modelling to obtain PK and
PD parameters is the preferred approach [37]. The
population approach differs from the standard two-stage
approach in the fact that the analysis is based on
simultaneous analysis of all data of the entire population,
while still taking into account that different observations
come from different patients (Fig. 3b). Additionally, the
population approach allows not only for the analysis of
dense data, but also for sparse (limited number of
observations per individual) and unbalanced data (unequal
distribution of observations in various parts of the concen-
tration–time profile in the individuals) or a combination of
both. Finally, both the inter-individual and intra-individual
variability are separately estimated in the dataset using this
approach.
As a result of this methodology, when designing a
paediatric study of which the data will be analysed using
the population approach, it is advisable to collect samples at
different times (or time windows) or to set alternating
sampling schemes in subgroups of patients. This also
means that (part of the) samples can be collected during
routine clinical sampling. Consequently, the burden for
the child who participates in the trial is reduced and the
statistical power to develop a model describing the
concentration–time or concentration–effect profile is not
affected or improved.
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Fig. 2 Simulation of propofol
concentrations and response us-
ing COMFORT-B score versus
time based on developed PK
and PD models, after adminis-
tration of different doses of
propofol (0, 18, 30, and 36
mg/h) for a 10-kg and a 5-kg
non-ventilated infant in the first
night at the Intensive Care Unit
following craniofacial surgery.
Target COMFORT-B scores
are between 12 and 14 prefera-
bly. Reproduced from [Peeters
MY, Prins SA, Knibbe CA,
DeJongh J, van Schaik RH, van
Dijk M, et al. Propofol pharma-
cokinetics and pharmacodynam-
ics for depth of sedation in
nonventilated infants after major
craniofacial surgery. Anesthesi-
ology 2006 Mar;104(3):466-74.]
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represents a mixture of fixed and random effects. For the
fixed effects, a structural model describing the PK or PD is
chosen (e.g. a two-compartment model for PK or an Emax
model for PD). The random effects quantify the variability
that is not explained by the fixed effects. These random
effects include inter-subject and intra-subject random
variability (Fig. 4), which are both simultaneously and
separately estimated. It is often assumed that the variability
between subjects follows a normal distribution with a mean
of zero and variance ω
2. Equation 1 is used to describe the
relationship between individual and population parameter
estimates.
qi ¼ qmean  ehi ð1Þ
where θi represents the parameter of the ith subject, θmean
the population mean, and ηi the variability between
subjects. The residual error is generally described using a
proportional error (error is dependent on the concentration,
which means a higher absolute error at higher concen-
trations (Eq. 2) or an additive error (constant for all
observations (Eq. 3) or a combination of both. This means
for the jth observed concentration of the Ith individual the
relation (Yij):
Yij ¼ cpred;ij   1 þ "ij
  
ð2Þ
Yij ¼ cpred;ij þ"ij ð3Þ
where cpred is predicted concentration and εij is a random
variable with a mean of zero and a variance of σ
2.
In general, model building requires three different steps.
First, a structural model (fixed effects) has to be designed,
then a statistical sub-model (random effects) has to be
developed and in the final step a covariate sub-model is
identified.
The structural model describes the overall trend in the
data. The choice of structural model (e.g. one-, two- or
three-compartment model for PK and an Emax model for
PD) is to be based upon the best a priori information about
the drug to be studied [40]. The structural model uses fixed
effects parameters such as clearance and volume of
distribution for PK or Emax and EC50 for PD. The
population values for these parameters are called typical
values (TV).
After selecting the structural model, the statistical sub-
model, which accounts for the inter-individual as well as
the residual variability, is chosen and tested. Information on
the inter- and intra-individual or residual variability is of
clinical value, because it describes differences in clinical
response between and within patients and may therefore
provide guidance for rational dose adjustments. With the
population approach, both these random effects are
obtained, apart from estimates of both the population
values (TV) and the individual values of PK and PD
parameters (so-called post hoc parameter estimates).
In the final step the covariate sub-model is determined,
which expresses relationships between covariates and
parameters of the structural model (e.g. influence of body
weight on volume of distribution or clearance). Covariates
Fig. 3 Concentration–time profiles of the same study using two
different approaches. In a the standard two-stage approach is applied
to a rich dataset. b shows the population approach with mixed effect
modelling applied to the same dataset using only two data points for
each individual so that a sparse dataset is created. In a, in each of the
six individuals 10 samples are available. The different symbols
correspond to different individuals. Each black line corresponds to a
separate fit to the 10 data points of each individual. In b, which uses
the mixed effect modelling approach, two samples of the 10 per
subject in a are used. The different symbols correspond to the six
different individuals. The black line illustrates the concentration–time
plot based on the population mean values of the PK parameters
(PRED). The grey lines show the plots of the individual patients,
which are based on the population mean values together with the
measured concentrations of the specific individual (IPRED)
Eur J Clin Pharmacol (2011) 67 (Suppl 1):S5–S16 S9can be individual-specific (age, body weight, genetic
profile, etc.) or time-varying (renal function, haemody-
namic parameters, body temperature, etc.). The covariate
analysis will be explained in more detail in the following
section.
As these three models are inter-related, the choice of the
structural (and statistical) model may affect the choice of
the covariate model and vice versa. The process of finding a
model that adequately describes the data is thus an
elaborate task, where model checking/refining is performed
in several steps. To assess model fit in relation to the
observed concentrations or effect measures, scatter plots or
the so-called goodness-of-fit plots are created (see Validation
of the PK–PD models). Free software packages (Xpose,
PSN, etc.) are available to generate these plots.
The most commonly used software package for model
building, which is also supported by the European
Medicines Agency (EMEA) is the non-linear mixed-effect
modelling program NONMEM (GloboMax/ ICON, Ellicott
City, MD, USA) [4, 41–43]. NONMEM estimates param-
eters (e.g. clearance, volume of distribution or EC50) via a
maximum likelihood approach. This means that with the
given data, the estimations of the parameters are those that
occur with the highest probability. Alternative software
packages that can be used are, for example, Monolix,
WinNonMix, USC*PAC, which uses non-parametric max-
imum likelihood methods [44], or ADAPT, using maximum
a posteriori (MAP) methods [45].
Covariate analysis
To determine the optimal dose based on the individual
characteristics of a patient, a covariate analysis has to be
performed [40, 46, 47]. The aim of the covariate analysis is
to identify specific predictors (covariates) of PK and PD
variability and can typically be studied in population
models. Covariate analysis involves the modelling of the
distribution of the individual parameter estimates as a
function of covariates, which can be of demographic (e.g.
age, body weight, gender), patho-physiological (e.g. renal
or hepatic function) and genetic/environmental origin, and/
or be the result of the concomitant use of other drugs,
which may influence the PK and/or PD. The identification
of predictive covariates for variability provides the scien-
tific basis for rational and individualised, patient-tailored
dosing schemes.
The influence of developmental changes in childhood
can be explored primarily by using size and/or age as
covariates. Size (body weight) can be incorporated into the
model using two different approaches. The first approach,
the “allometric size approach”, includes size a priori by
using a body weight-based exponential equation with a
fixed exponent of 0.75 for clearance and 1 for volume of
distribution [48–52]. Once size is incorporated in the model
using this fixed method, the influence of age is investigat-
ed, being the difference between the actual value of the PK
parameter and the 0.75 allometric equation. When incorpo-
rating age as a covariate, different age descriptors may be
used like postmenstrual age (PMA), gestational age (GA) or
postnatal age (PNA) [53]. The choice of any of these age
descriptors is based on the results of the systematic
covariate analysis as described below [50, 54]. In the
second approach, the “systematic covariate analysis”, body
weight is regarded as a covariate as any other, which means
that the descriptive properties on the PK parameters are
evaluated in a systematic covariate analysis as described
below [55–57].
Fig. 4 In a, the inter-individual variability among three individuals
who received the same dose is shown. b presents the intra-individual
or residual variability by showing the concentration–time profile after
repeated administration. Both these random variables are assumed to
be normally distributed with a mean of zero and a variance of ω
2 or
σ
2 respectively
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covariates, scatter plots and summary plots of individual
parameter estimates and/or weighted residuals versus cova-
riates are used to screen for appropriate covariates to include
in the covariate sub-model. Additionally, these plots are used
to explore the nature of the influence of the covariate (linear,
exponential, allometric, subpopulations, etc.). Likely candi-
date covariates are then added to the model (forward
inclusion). The influence of each covariate on the parameters
is examined separately and compared with the simple model
(no covariates). To assess whether the model with the
covariate statistically improved the fit to the data, the
difference between their objective function value, referred
to as the log–likelihood ratio, is calculated. This ratio is
assumed to be Chi-squared distributed, which means that a
reduction in objective function of 3.84 is considered to be
significant (P<0.05) [43, 58]. In addition, the reduction in
objective function, goodness-of-fit plots of the simple model
and covariate model are explored for diagnostic purposes.
Furthermore, the confidence interval of the parameter
estimates, the correlation matrix (indicates the relationship
between two structural parameters) and visual improvement
of the individual plots are used to evaluate the model.
Finally, a superior model is expected to reduce the inter-
subject variance and/or the residual error terms. This
procedure of covariate modelling implies that each covariate
is only implemented if it can be fully justified by the data
and the results of the statistic evaluations.
When two or more covariates are found to significantly
improve the model, the covariate that reduced the objective
function most is included in the model after which the other
covariates are tested again for their significance. After all
covariates that significantly improved the objective function
are added to the simple model, a backward deletion is
performed, which means that each covariate is removed
from the full model, one at a time (the one that causes the
smallest increase in objective function first). Retaining or
removing the covariate is statistically tested by the use of
the objective function (Chi-squared test) until each cova-
riate has been tested.
In datasets containing sparse data, there may not be
enough information to accurately estimate inter- and intra-
individual variability. This causes the values of these
parameters to shrink to 0, resulting in individual parameter
estimates that are closer to the population parameter
estimates than they really are. This phenomenon is called
shrinkage [59]. Shrinkage may cause individual predictions,
individual parameter estimates and diagnostics based on
them to be less reliable. It can also hide, falsely introduce or
distort the shape of covariate relationships.
Shrinkage is the result of the properties of the data and is
therefore difficult to avoid. One can only be aware of the
presence of shrinkage, realise the influence it may have on
the covariate analysis and use diagnostics other than those
based on individual predictions or individual weighted
residuals in the model building and model evaluation
procedures.
Validation of PK–PD models
TheobjectiveofaPKorPK–PDmodellingexerciseisusually
notjusttodescribethedatasetofthesampleofindividualsthat
were studied. Generally, models are used to simulate which
concentrations and/or effects and their variability can be
expected when different doses are given to future patients.
These simulations may therefore lead to optimised dosing
recommendations or to optimisation of new studies for the
entire population to which the sample of individuals belongs.
Itisoftensaidthat“allmodelsarewrong,butsomeareuseful”
[60]. In order to define whether a model is useful and valid
for clinical and trial simulations, thorough evaluation and
validation of the model is necessary. Although validations of
PK models are only performed in 17% of the published
paediatric studies [4] and in 28% of the adult studies [61],
proper model validations are an essential step in model
building. For this purpose, different evaluation and validation
methods are available. As described before [62], a proper
validation and evaluation procedure includes an internal
model evaluation followed by an external evaluation and a
prospective clinical study.
The first evaluation method is the basic internal model
validation used to assess whether the model is able to
describe the learning dataset (the dataset used to develop
the model) accurately and without bias. This evaluation
should actually be considered the final stage of the model
building procedure. Subsequently, in the external evalua-
tion, it is assessed whether the model is able to describe one
or more external datasets (the datasets other than the one
used to develop the model) adequately. Alternatively, if a
dataset is sufficiently large the original dataset may be split
in two so that the model is developed using one part (about
two thirds) of the dataset and evaluated externally using the
other part (one third) of the dataset. In paediatric studies, it
is then especially important to stratify the data correctly and
ascertain that all age groups are represented in equal
proportions in both datasets.
Various techniques are available for the validation and
evaluation of population PK and PK–PD models (both for
internal and external validation procedures).
Basic goodness-of-fit plots
1. Individual predicted vs observed concentrations
2. Population predicted vs observed
3. (Conditional) weighted residual vs time
4. (Conditional) weighted residuals vs dependent variable
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residuals (CWRES) are calculated as follows:
WRES ¼
~ yi   EFO ~ yi ðÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CovFO ~ yi ðÞ
p ð4Þ
CWRES ¼
~ yi   EFOCE ~ yi ðÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CovFOCE ~ yi ðÞ
p ð5Þ
where ~ yi is the vector of the measurements, E ~ yi ðÞ is the
expectation of the data and Cov ~ yi ðÞ is the covariance matrix
of the data [63].
These plots are used in model building, but can also be
used to ascertain that there is no trend or bias in the model
predictions of the final model. Furthermore, these plots can
be used for both the internal and external evaluation of the
model.
Bootstrap analysis In a bootstrap analysis new datasets are
generated by resampling from the original dataset and it is
therefore an internal validation of the model. The new
datasets are subsequently refitted to the original model,
yielding mean values and standard errors for every model
parameter.
A bootstrap analysis provides information on the
stability of the model and its dependence on specific
individuals in the learning dataset. With the freely available
PSN or Wings for NONMEM software packages an
automated bootstrap analysis can be performed.
Visual predictive check In a visual predictive check
(VPC) [64] a PK or PD profile is simulated a 100 to
1,000 times and lines for the median values and their 90%
prediction interval are plotted in a graph. The observed
values in the internal or external dataset are subsequently
plotted on top of this. It can then be visually checked
whether 90% of the observations are within the indicated
prediction interval and whether there is no bias in the
observations compared with the prediction interval. In
Fig. 5, two examples of a VPC are given, showing when a
model does not work and when a model does work on the
same data.
The VPC is a simulation-based diagnostic that can be
used when the PK or PD profiles for all individuals in the
dataset are similar and it allows for easy interpretation of
the result. For this diagnostic tool, there are no statistical
tests and all evaluations are based on visual assessment.
When the individual profiles are expected to deviate largely
from one another because there is for instance a large
variability in the time and amount of dose administrated, or
when there are many covariates, the use of this diagnostic
becomes more difficult.
Normalised prediction distributionerror Another simulation-
based diagnostic that can be used for both internal and
external validations is the normalised prediction distribution
error (NPDE) [65]. An example of an NPDE previously
published is shown in Fig. 6 [55]. This method yields
information on how accurate the model predicts the median
value of the observations and the variability within them.
The interpretation of this diagnostic is less straightforward
than for the VPC, but the advantage of this method is that it
can be used when the variability in dosing regimen (both in
time, amounts and rates) is high or when there is a large
A.
B.
Fig. 5 Two examples of a visual predictive check (VPC) are
illustrated based on the same dataset (warfarin concentrations and
prothrombin complex activity [PCA]) using two different models. In a
the VPC of the effect compartment is shown, while in b the VPC of
the turnover model is demonstrated. Both real (grey) and simulated
(black) data are displayed with mean (thick lines) and 95% intervals
(thin lines). Based on both graphics, the turnover model is the most
appropriate model since real and simulated lines are in good
agreement. Reproduced from [Karlsson, M. O. and N. H. G. Holford
(2008). “A Tutorial on Visual Predictive Checks.” PAGE 17 (2008)
Abstr 1434 (www.page-meeting.org/?abstract=1434)]
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the case for data obtained during routine paediatric clinical
practice. Software (e.g. NPDE add-on package for R) [66]
to perform this analysis is freely available. For the NPDE,
besides visual evaluation of the plots, statistical tests are
available. These statistical tests are, however, reported to be
highly sensitive and powerful, so that decisions for the
model should primarily be based on visual assessments. An
example is the statistically significant deviation of zero of
the mean value because of the large number of data, while
the actual deviation is small (e.g. 0.074) and not of clinical
relevance.
If the model performed well in both evaluation proce-
dures, the dosing algorithm that results from the PK–PD
model needs to be tested and challenged in a prospective
(clinical) trial. If the predictive performance of the model is
corroborated by the trial it can be used with confidence in
clinical practice.
Optimal design of paediatric studies
When new population PK–PD studies are performed, it
is important to design these studies in the most efficient
manner possible to obtain maximum information about
the PK and PD parameters so that they can be
determined with the highest precision [51, 67]. When
designing PK–PD studies in paediatrics certain factors
need to be taken into account, e.g. the age range of the
paediatric group, the therapeutic index, the possibility of
collecting blood samples, the availability of validated PD
endpoints for children and the availability of sensitive
analytical methods.
When optimising a PK or PK–PD study design, using
literature data from adults or children of different age
ranges or possibly in vitro or pre-clinical data, a concen-
tration–time or effect–time profile for a study can be
simulated. This can help to identify possible shortcomings
in the design or to perform a power analysis. Alternatively,
Table 1 Factors influencing the required number of patients and/or samples per patient
Factor Number of patients/samples
Study of PK only Relatively small number of patients/samples
Study of PK–PD relationship Relatively high number of patients/samples
Even distribution of covariates (age, body weight) ↓ Number of patients/samples
↑ Number of changes in dose ↑/- Number of patients/samples (depending on other aspects of the study
design)
↑ Number of samples/child ↓ Number of patients
Use of optimal sampling strategies ↓ Number of patients/samples
Different sampling windows (e.g. two or three sampling
schemes)
↓ Number of patients/samples
Fig. 6 Example of a normalised prediction distribution error (NPDE)
analysis, which shows the NPDE distributions for morphine. The
normal distribution is represented by the solid line. The values for the
mean and standard deviation of the observed NPDE distribution are
given below the histogram, with an asterisk indicating a significant
difference of a mean of 0 and a variance of 1 at the P<0.05 level, as
determined by the Wilcoxon signed rank test and Fisher’s test for
variance. The distribution of NPDE vs time after the first dose and
NPDE vs the log of the concentrations are also shown. The dotted
lines represent the 90% distribution of the NPDE. Reproduced from
[Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW,
van Dijk M, et al. Morphine glucuronidation in preterm neonates,
infants and children younger than 3 years. Clin Pharmacokinet
2009;48(6):371-85] with permission from Wolters Kluwer Health |
Adis (© Adis Data Information BV [2006]). All rights reserved
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[67] and PFIM [69]) that can help to identify the optimal
number and time points of observations in a study based on
the prior information on a drug [70]. To determine the
appropriate sample size certain factors, which are summar-
ised in Table 1, need to be taken into account. Each of these
factors can influence the required number of patients and/or
samples in a positive or negative way. In a study by Peeters
et al. [32] only 24 patients (aged between 3 and 24 months)
were required to determine both the PK and PD, since rich
sampling was performed (a median of 11 samples per child)
and no covariates were found in the relatively homoge-
neous population. This is in contrast to a study performed
by Knibbe et al. [55], in which 250 children were included.
This higher number was required because in addition to the
large dispersion in age from (pre-term) neonates up to
toddlers of 3 years of age, only 1 to 4 samples were
available for each subject. Moreover, infusion rates and
additional bolus doses varied for each child during the
study to obtain the desired analgesic effect. In another
example [71], only 6 patients (aged between 1 and 5 years)
were required, in which 7 samples per patient were
collected. This lower number of patients (n=6) compared
with the study by Peeters et al. (n=24) can be explained
because there often exists a lower variability in PK than in
PD, which results in a lower number of patients required
(Table 1).
Conclusions and perspectives
In view of the European Regulation, which came into force
in 2007, it now seems time to use the progress that has been
made in the field of integrated PK–PD modelling [72]t o
develop rational and individualised dosing schemes for
children. Because of the possibility of analysing sparse and
unbalanced datasets, thereby minimising the burden for
each child, population PK–PD modelling and simulation
using non-linear mixed effect modelling has become the
preferred tool to develop effective and safe dosing regimens
for children. Specifically in paediatrics, where develop-
mental changes have to be taken into account, which may
influence the PK and/or the PD of the drugs, this advanced
statistical tool is of critical value.
Before dosing regimens can be tested in clinical practice,
proper validations of the models should be performed, for
which adequate tools have recently been developed.
Besides internal and external validation, prospective clini-
cal trials, which allow for the evaluation of the model-based
dosing regimens, are needed, not only to adjust the
proposed dosing regimen, but also to convince paediatri-
cians to use the information that has been generated using
these modelling exercises.
Furthermore, one of the future goals may be to explore
the possibilities of cross-validation of the models, in which
the reported influences of developmental changes on a
certain PK or PD parameter of one drug are evaluated for
use in another drug that goes through the same metabolic
route or shares the same mechanism of action. In this
respect, physiologically based pharmacokinetic (PBPK)
models are needed. PBPK models consider the physiolog-
ical and biochemical processes by using in vitro data to
describe the PK of drugs [73, 74]. The combination of these
two approaches may use the information that is already
available in an optimal way in defining effective and safe
dosing regimens for each individual patient.
In conclusion, analyses of paediatric data using
population PK–PD modelling and covariate analysis will
result in individualised dosing regimens for children of
different ages, body weights and genetic backgrounds.
Thus, population PK–PD modelling constitutes an inno-
vative approach to the study of drug effects in this very
special patient population, which is otherwise difficult to
study.
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